Lewis Titterton - Anixa Biosciences Independent Director
| ANIX Stock | USD 3.07 0.06 1.99% |
Director
Mr. Lewis H. Titterton, Jr., is the Lead Independent Director of the Company. He previously served as a director of the Company from August 2010 through August 2016, as the Chairman of the Board from July 2012 through August 2016, and interim Chief Executive Officer from August 2012 until September 2012. Mr. Titterton is currently Chairman of the Board of NYMED, Inc., a diversified health services company, and he serves on the board of directors of ParkerVision, Inc., a publicly traded wireless technology company. His background is in high technology with an emphasis on health care and he was the Chairman of the Board of Directors of NYMED, Inc. since 1989. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. Mr. Titterton also served as one of our Directors from July 1999 to January 2003. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University. Mr. Titterton was involved with our Company as a director or investor for over twenty years since 2018.
| Age | 73 |
| Tenure | 6 years |
| Address | 3150 Almaden Expressway, San Jose, CA, United States, 95118 |
| Phone | 408 708 9808 |
| Web | https://www.anixa.com |
Lewis Titterton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lewis Titterton against Anixa Biosciences stock is an integral part of due diligence when investing in Anixa Biosciences. Lewis Titterton insider activity provides valuable insight into whether Anixa Biosciences is net buyers or sellers over its current business cycle. Note, Anixa Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Anixa Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lewis Titterton over two weeks ago Acquisition by Lewis Titterton of 15009 shares of Anixa Biosciences at 3.28 subject to Rule 16b-3 | ||
Lewis Titterton over a month ago Acquisition by Lewis Titterton of 45000 shares of Anixa Biosciences at 4.84 subject to Rule 16b-3 | ||
Lewis Titterton over a month ago Acquisition by Lewis Titterton of 6000 shares of Anixa Biosciences subject to Rule 16b-3 | ||
Lewis Titterton over six months ago Exercise or conversion by Lewis Titterton of 16000 shares of Anixa Biosciences subject to Rule 16b-3 |
Anixa Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2809) % which means that it has lost $0.2809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4302) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 30.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 181.4 K in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gilbert Labrucherie | Rezolute | 44 | |
| David Welch | Rezolute | 56 | |
| Barry Simon | Cue Biopharma | 53 | |
| Samir Patel | Rezolute | 46 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Bahija Jallal | AN2 Therapeutics | N/A | |
| Frank Morich | Cue Biopharma | 63 | |
| Kerry Clark | AN2 Therapeutics | 63 | |
| Peter Kiener | Cue Biopharma | 63 | |
| Hoyoung Huh | Rezolute | 47 | |
| Young Sung | Rezolute | N/A | |
| William Ryan | AN2 Therapeutics | 71 | |
| Steven McKnight | Cue Biopharma | 63 | |
| John Short | AN2 Therapeutics | 70 | |
| YoungJin Kim | Rezolute | N/A | |
| Paul Strickland | Annovis BioInc | 37 | |
| Tae Kim | Rezolute | 34 | |
| Robert Dixon | AN2 Therapeutics | 60 | |
| Elizabeth Tallett | AN2 Therapeutics | 67 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 |
Anixa Biosciences Leadership Team
Elected by the shareholders, the Anixa Biosciences' board of directors comprises two types of representatives: Anixa Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anixa. The board's role is to monitor Anixa Biosciences' management team and ensure that shareholders' interests are well served. Anixa Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anixa Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amit Kumar, Chairman of the Board and Presidentident, CEO | ||
| Dean Krouch, IR Contact Officer | ||
| John Roop, Senior Engineering | ||
| Pamela Garzone, Chief Officer | ||
| Thomas Schlumpberger, Ex Diagnostics | ||
| Arnold Baskies, Director | ||
| Richard Williams, Independent Director | ||
| John Monahan, Independent Director | ||
| Michael Catelani, CFO, COO | ||
| John Monanhan, Independent Director | ||
| David Cavalier, Director | ||
| Dale Fox, Independent Director | ||
| Lewis Titterton, Independent Director | ||
| Bruce Johnson, Independent Director |
Anixa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anixa Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (57.45) % | ||||
| Current Valuation | 71.38 M | ||||
| Shares Outstanding | 31.9 M | ||||
| Shares Owned By Insiders | 4.90 % | ||||
| Shares Owned By Institutions | 13.89 % | ||||
| Number Of Shares Shorted | 575.88 K | ||||
| Price To Earning | (51.83) X | ||||
| Price To Book | 4.11 X |
Pair Trading with Anixa Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anixa Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anixa Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Anixa Stock
| 0.89 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
| 0.87 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.84 | OPT | Opthea | PairCorr |
| 0.82 | CNTA | Centessa Pharmaceuticals Downward Rally | PairCorr |
| 0.79 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Anixa Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anixa Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anixa Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anixa Biosciences to buy it.
The correlation of Anixa Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anixa Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anixa Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anixa Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Anixa Stock analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Anixa Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anixa Biosciences. If investors know Anixa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anixa Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 0.007 | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Anixa Biosciences is measured differently than its book value, which is the value of Anixa that is recorded on the company's balance sheet. Investors also form their own opinion of Anixa Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Anixa Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anixa Biosciences' market value can be influenced by many factors that don't directly affect Anixa Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anixa Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anixa Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anixa Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.